U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H36N6O5
Molecular Weight 584.6654
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PD-176252

SMILES

COC1=CN=C(C=C1)C5(CNC(=O)[C@](C)(CC2=CNC3=C2C=CC=C3)NC(=O)NC4=CC=C(C=C4)[N+]([O-])=O)CCCCC5

InChI

InChIKey=NNFUWNLENRUDHR-HKBQPEDESA-N
InChI=1S/C32H36N6O5/c1-31(18-22-19-33-27-9-5-4-8-26(22)27,37-30(40)36-23-10-12-24(13-11-23)38(41)42)29(39)35-21-32(16-6-3-7-17-32)28-15-14-25(43-2)20-34-28/h4-5,8-15,19-20,33H,3,6-7,16-18,21H2,1-2H3,(H,35,39)(H2,36,37,40)/t31-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12909192 | https://www.ncbi.nlm.nih.gov/pubmed/17035523

PD 176252 is a competitive antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide preferring (BB2) receptors. PD176252 inhibited tumor growtn in preclinical model of lung cancer, and exhibited synergy with EGFR inhibitor in the model of head and neck cancer. PD176252 demonstrated anxiolytic properties in preclinical models.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [Ki]
0.15 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
2009-08
PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.
1998-09-22
Patents

Sample Use Guides

Female athymic Balb/c nude mice (Taconic Farms), 4–5 weeks old, were housed in a pathogen-free temperature controlled isolation room, with a diet consisting of autoclaved rodent chow and autoclaved water given ad libitum. NCI-H1299 cells (1*10^7) were injected into the right flank of each mouse by subcutaneous injection. Palpable tumors were observed in approximately 90% of the mice after 1 week. Polyethylene glycol (PEG, 100 Al) or PD176252 (10 or 1 ug in 100 ul of PEG 400) were injected daily by gavage. In anxiety model, PD176252 was administered to rats intraperitoneally at doses 3.75-7.5 mg/kg or intracerebloventicularly, 100-200 ng/rat.
Route of Administration: Other
Growth studies in vitro were conducted using the MTT colorimetic assays. NCI-H1299 cells (104/well) were placed in SIT medium and various concentrations of PD176252 added. After 4 days, MTT (Sigma) was added. After 4 h, 150 Al of dimethylsulfoxide was added. After 16 h, the optical density at 570 nm was determined. The IC50 for PD176252 was 5 and 7 AM using NCI-H1299 and H345 cells, respectively.
Name Type Language
1H-INDOLE-3-PROPANAMIDE, N-((1-(5-METHOXY-2-PYRIDINYL)CYCLOHEXYL)METHYL)-.ALPHA.-METHYL-.ALPHA.-((((4-NITROPHENYL)AMINO)CARBONYL)AMINO)-, (.ALPHA.S)-
Preferred Name English
PD-176252
Common Name English
1H-INDOLE-3-PROPANAMIDE, N-((1-(5-METHOXY-2-PYRIDINYL)CYCLOHEXYL)METHYL)-.ALPHA.-METHYL-.ALPHA.-((((4-NITROPHENYL)AMINO)CARBONYL)AMINO)-, (S)-
Systematic Name English
Code System Code Type Description
CAS
204067-01-6
Created by admin on Mon Mar 31 22:41:38 GMT 2025 , Edited by admin on Mon Mar 31 22:41:38 GMT 2025
PRIMARY
FDA UNII
JT21Y57650
Created by admin on Mon Mar 31 22:41:38 GMT 2025 , Edited by admin on Mon Mar 31 22:41:38 GMT 2025
PRIMARY
PUBCHEM
9829828
Created by admin on Mon Mar 31 22:41:38 GMT 2025 , Edited by admin on Mon Mar 31 22:41:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID90431389
Created by admin on Mon Mar 31 22:41:38 GMT 2025 , Edited by admin on Mon Mar 31 22:41:38 GMT 2025
PRIMARY